Nothing Special   »   [go: up one dir, main page]

BRPI0417489A - método de predição da potência de rnai - Google Patents

método de predição da potência de rnai

Info

Publication number
BRPI0417489A
BRPI0417489A BRPI0417489-5A BRPI0417489A BRPI0417489A BR PI0417489 A BRPI0417489 A BR PI0417489A BR PI0417489 A BRPI0417489 A BR PI0417489A BR PI0417489 A BRPI0417489 A BR PI0417489A
Authority
BR
Brazil
Prior art keywords
rnai
prediction method
power prediction
methods
predicting
Prior art date
Application number
BRPI0417489-5A
Other languages
English (en)
Inventor
Jonathan Hall
Dieter Huesken
J Rg Bernd Lange
Francois Jean-Charles Natt
Mischa Werner Henri Reinhardt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0417489A publication Critical patent/BRPI0417489A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

MéTODO DE PREDIçãO DA POTêNCIA DE RNAi. A presente invenção refere-se a métodos para a preparação de um algoritmo para a previsão da potência de RNAi de um reagente de RNAi. A invenção refere-se também a métodos para a previsão da potência de RNAi de um reagente de RNAi e métodos para a inibição da expressão de um dado gene alvo usando esse algoritmo.
BRPI0417489-5A 2003-12-10 2004-12-09 método de predição da potência de rnai BRPI0417489A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52843003P 2003-12-10 2003-12-10
PCT/EP2004/014037 WO2005059132A1 (en) 2003-12-10 2004-12-09 Rnai potency prediction method

Publications (1)

Publication Number Publication Date
BRPI0417489A true BRPI0417489A (pt) 2007-05-22

Family

ID=34699869

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417489-5A BRPI0417489A (pt) 2003-12-10 2004-12-09 método de predição da potência de rnai

Country Status (9)

Country Link
EP (1) EP1694843A1 (pt)
JP (1) JP2007523632A (pt)
KR (1) KR20060126499A (pt)
CN (1) CN1890370A (pt)
AU (1) AU2004298527A1 (pt)
BR (1) BRPI0417489A (pt)
CA (1) CA2545675A1 (pt)
RU (1) RU2006124515A (pt)
WO (1) WO2005059132A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006016365B4 (de) * 2006-04-05 2015-08-13 Qiagen Gmbh RNA-Interferenz Tags
WO2008071771A2 (en) * 2006-12-15 2008-06-19 Novartis Ag Inhibition of gpr4
CA2678055C (en) 2007-04-10 2016-02-16 Qiagen Gmbh Rna interference tags
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
CN101625732B (zh) * 2009-08-03 2011-11-30 杭州电子科技大学 江河潮水水位的预测方法
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
RU2014124184A (ru) 2011-11-15 2015-12-27 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
EP2866831A1 (en) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
EP3368566A1 (en) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w and biliary tract cancers
CN109360604B (zh) * 2018-11-21 2021-09-24 南昌大学 一种卵巢癌分子分型预测系统

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212302D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Method of selecting targets for gene silencing by RNA interference

Also Published As

Publication number Publication date
AU2004298527A1 (en) 2005-06-30
WO2005059132A1 (en) 2005-06-30
CA2545675A1 (en) 2005-06-30
RU2006124515A (ru) 2008-01-20
CN1890370A (zh) 2007-01-03
KR20060126499A (ko) 2006-12-07
EP1694843A1 (en) 2006-08-30
JP2007523632A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
BRPI0417489A (pt) método de predição da potência de rnai
EP4242325A3 (en) Methods for spatial analysis using targeted rna depletion
DE60331321D1 (de) Verfahren zur wirksamen rna-interferenz in säugerzellen
BRPI0612409B8 (pt) composições de tensoativos à base de ácido peroxicarboxílico e método de reduzir a população de microorganismos em um objeto
WO2008015384A8 (en) Method for predicting protein aggregation and designing aggregation inhibitors
MX2008002149A (es) Composiciones de arnt y sus usos.
IL194741A (en) Method for providing login information at @ terminal
NO20075471L (no) Betjening av en eller flere drivstoffautomater
CR9520A (es) Inhibidores de la fosfolipasa a2 citosolica
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
BRPI0519285A2 (pt) biomaterial implatável e método de produzir o mesmo
WO2007038788A3 (en) Small interfering rnas as non-specific drugs
TWI317811B (pt)
BRPI0513310A (pt) análogos de tetrapeptìdeo
TW200738270A (en) Method of treating depression using a TNFα antibody
DK1838355T3 (da) Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde
ATE484231T1 (de) Vorrichtung für vorhersage von muskel/skelett- erkrankungen
ATE414535T1 (de) Trägerproteine für impfstoffe
EP2001142A4 (en) METHOD AND APPARATUS FOR DOWNLINK BEAM FORMATION OF CODE AND TIME DIVISION MULTIPLE ACCESS SYSTEM
MX2009013646A (es) Metodos de diagnostico y tratamiento del cancer.
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
WO2004066183A3 (en) Microrna
WO2006132739A3 (en) Novel chemical compounds
DE602007008872D1 (de) Mikrowellengestützte deglycosylierung von proteinen zur molekulargewichtsbestimmung durch massenspektrometrie
GB2472754A (en) A method of identifying a target simplex

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.